Tuberculosis small capacity-building workshop (practical training)

Dates/duration

March 2021 / 2 days

Location

Practical training at San Raffaele Scientific Institute in Milan, Italy (depending on the COVID-19 situation)

Objectives/learning outcomes

Upon completion of the practical training, participants will be able to:

  • perform phenotypic-based drug susceptibility testing (DST) to new and repurposed drugs for MDR-TB treatment;
  • interpret reports from automated systems for DST by using standard and/or extended DST protocols;
  • perform MIC testing for M. tuberculosis using the microdilution methodology;
  • describe the main methodologies used for NTM identification
  • familiarise with the methodologies used for drug susceptibility testing of NTMs.

Target audience

Participants identified within the network. TB laboratory mid and senior level experts with at least three years of experience working on TB and/or in a microbiology laboratory.

Description

This training seeks to strengthen capacity in Member States with regard to the diagnosis of tuberculosis. The program is developed under the European Reference Laboratory Network for Tuberculosis (ERLTB-Net, ECDC/GRANT/2018/001), by the consortium of partners managing the implementation of activities based on identified needs of the network. Specifically, this course will cover advanced topics in TB laboratory diagnostics focusing primarily on phenotypic-based drug susceptibility testing (DST) for both M. tuberculosis complex and non-tuberculous mycobacteria (NTMs). In this practical training, participants will have the opportunity to perform DST for new and repurposed anti-TB drugs, and MIC testing using both 96-wells microtiter plates and BACTEC Mycobacteria Growth Indicator Tube (MGIT) 960 system. In addition, the workshop will include a panel discussion in which participants will have the opportunity to share experience and considerations on the implementation of new TB tests into laboratory algorithms, on the impact of new tests on clinical decision-making and therapeutic choices, and on the cost-effectiveness in routine programmatic settings.

Note: This course is not open for public enrolment. Participation is through invitation by the focal point of the respective disease programme or function areas which is guided by the framework of collaboration between ECDC and the Coordinating Competent Bodies of Member States.